Register for email alerts and news feeds:
This journal | BMJ Group
rss
Heart 2009;95:1020-1022; doi:10.1136/hrt.2009.165969
Copyright © 2009 BMJ Publishing Group Ltd & British Cardiovascular Society

Featured correspondence

Letters

Thiazolidinediones may contribute to the intramyocardial lipid accumulation in diabetic myocardium: effects on cardiac function

R Marfella1, M Portoghese2, F Ferraraccio3, M Siniscalchi4, M Babieri1, C Di Filippo5, M D’Amico5, F Rossi5, G Paolisso1

1 Department of Geriatrics and Metabolic Diseases Second University of Naples, Naples, Italy
2 Cardiovascular Surgery Unit, Sassari Hospital, Sassari, Italy
3 Department of Clinical, Public and Preventive Medicine Second University of Naples, Naples, Italy
4 Department of Cardiovascular Diseases, Agropoli Hospital, Agropoli, Italy
5 Department of Experimental Medicine Second University of Naples, Naples, Italy

Correspondence to:
Professor R Marfella, Second University of Naples, Piazza Miraglia, 1 Naples, 80138 Italy; raffaele.marfella@unina2.it

The first 150 words of the full text of this article appear below.

To the editor: Treatment with thiazolidinedione (TZD), an agonist of peroxisome proliferator-activated receptor-{gamma} (PPAR{gamma}), has been associated with a significant increase in heart failure in type 2 diabetic patients.1 These ligand-activated nuclear transcription factors (rosiglitazone and pioglitazone) are implicated in adipogenesis and tissue lipid accumulation.2 Indeed, myocyte overexpression of PPAR{gamma}, leads to lipotoxic cardiomyopathy in both transgenic mice overexpressing PPAR{gamma} and TZD-treated diabetic mice.3 Thus, while PPAR{gamma} agonists appear to have beneficial effects on metabolic control,4 their direct actions on myocardium may impair heart function, inducing lipid accumulation. To examine these concerns, we analysed lipid accumulation and PPAR{gamma} expression in myocardial biopsy specimens obtained from type 2 diabetic patients with and without TZD treatment who underwent surgical valve replacement for mitral stenosis (MS), and related them to the heart function.

Nineteen non-TZD-treated and 13 TZD-treated (>=24 weeks of monotherapy in the previous year) type 2 diabetic . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.